Nerandomilast in idiopathic pulmonary fibrosis: data from the whole follow-up period of the FIBRONEER-IPF trial - PubMed
5 hours ago
- #nerandomilast
- #idiopathic pulmonary fibrosis
- #clinical trial
- Nerandomilast met the primary endpoint in the FIBRONEER-IPF trial by reducing decline in forced vital capacity at week 52 in patients with idiopathic pulmonary fibrosis.
- The study assessed the effects of nerandomilast over the full follow-up period, focusing on time to first acute exacerbation, hospitalization for respiratory cause, or death.
- Hazard ratios for the key secondary endpoint and death showed no significant effect for nerandomilast 9 mg bid, but nerandomilast 18 mg bid was associated with a numerically lower risk of death.
- Adverse events leading to treatment discontinuation were slightly higher in the nerandomilast groups compared to placebo.
- Nerandomilast demonstrated a favorable safety profile with a low rate of discontinuation due to adverse events.